Influence of chronic administration of clozapine or of S 16924 upon their ability to inhibit the induction of catalepsy by haloperidol
| Chronic (Dose) | Vehicle | Clozapine (10.0) | Vehicle | S 16924 (2.5) | |||||
|---|---|---|---|---|---|---|---|---|---|
| Acute (Dose) | Vehicle | Clozapine (10.0) | Vehicle | Clozapine (10.0) | Vehicle | S 16924 (2.5) | Vehicle | S 16924 (2.5) | |
| Catalepsy (sec) | 28.2 ± 0.8 | 8.7 ± 2.75-a | 25.9 ± 2.1 | 10.4 ± 5.25-a | 29.3 ± 0.6 | 16.7 ± 3.55-a | 29.5 ± 0.5 | 2.6 ± 1.65-a | |
Doses are in mg/kg, s.c. All animals received acute haloperidol (2.5 mg/kg, s.c.). Data are means ± S.E.M.s for duration of catalepsy (sec). ANOVA as follows. Acute S 16924, F (1,32) = 57.6, P < .001; chronic S 16924, F (1,32) = 7.2, P < .01 and interaction, F (1,32) = 7.5, P < .01. Acute clozapine, F (1,34) = 42.9, P < .001; chronic clozapine, F (1,34) = 0.1, P > .05 and interaction, F (1,34) = 0.6, P > .05. Asterisks denote significance of differences to respective acute vehicle values in Newman-Keuls test following ANOVA.
↵5-a P < .05.